Oxidative stress is activated by free fatty acids in cultured human hepatocytes

Metabolic Syndrome and Related Disorders

Volumn 9, Issue 5, 2011, Pages 397-401

  Soardo, Giorgio ^a   Donnini, Debora ^a   Domenis, Liana ^a   Catena, Cristiana ^a   De Silvestri, Daniele ^a   Cappello, Dario ^a   Dibenedetto, Alessia ^a   Carnelutti, Alessia ^a   Bonasia, Vincenzo ^a   Pagano, Claudio ^b   Sechi, Leonardo A ^a  

^a UNIVERSITY OF UDINE   (Italy)

^b UNIVERSITY OF PADOVA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCYSTEINE; ADIPONECTIN; BIOCHEMICAL MARKER; FATTY ACID; GLUTATHIONE; INDUCIBLE NITRIC OXIDE SYNTHASE; INSULIN RECEPTOR; MALONALDEHYDE; MESSENGER RNA; NITRIC OXIDE; PLASMINOGEN ACTIVATOR INHIBITOR;

ARTICLE; CELL STRAIN HEPG2; CONTROLLED STUDY; ENDOTHELIUM CELL; GENE EXPRESSION; HUMAN; HUMAN CELL; LIVER CELL CULTURE; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; THROMBOSIS;

ADIPONECTIN; ANTIOXIDANTS; CELLS, CULTURED; FATTY ACIDS; FATTY ACIDS, NONESTERIFIED; FATTY LIVER; GLUTATHIONE; HEPATOBLASTOMA; HEPATOCYTES; HUMANS; NITRIC OXIDE; NITRIC OXIDE SYNTHASE TYPE II; OXIDATIVE STRESS; RECEPTOR, INSULIN; RISK; THROMBOSIS;

EID: 80053518247     PISSN: 15404196     EISSN: 15578518     Source Type: Journal    
DOI: 10.1089/met.2010.0140     Document Type: Article

References (34)

1. Adams LA, Angulo P. Recent concepts in non alcoholic fatty liver disease. Diabet Med 2005;22:1129-1133. (Pubitemid 41224168)
2. McCullough AJ. Pathophysiology of non alcoholic statohepatitis. J Clin Gastroenterol 2006;40(Suppl 1):S17-S29.
3. Marchesini G, Marzocchi R, Agostini F, Bugianesi E. Non alcoholic fatty liver disease and the metabolic syndrome. Curr Opin Lipiodol 2005;16:421-427. (Pubitemid 41017626)
4. Neuschwander-Tetri BA. Non alcoholic steato-hepatitis and the metabolic syndrome. Am J Med Sci 2005;330:326-335. (Pubitemid 41831904)
5. Lavine JE, Schwimmer B. Non alcoholic fatty liver disease in the pediatric population. Clin Liver Dis 2004;8:549-558. (Pubitemid 39141142)
6. Eckel RH, Grundy SM, Zimmet PZ. The metabolic syndrome. Lancet 2005;365:1415-1428. (Pubitemid 40523737)
7. Villanova N, Moscatiello S, Ramilli S. Endothelial dysfunction and cardiovascular risk profile in non alcoholic fatty liver disease. Hepatology 2005;42:473-478.
8. Targher G, Bertolini L, Padovani R. Increased prevalence of cardiovascular disease among type 2 diabetic patients with non-alcoholic fatty liver disease. Diabet Med 2006;23:403-409.
9. Ong JP, Pitts A, Younossi ZM. Increased overall mortality and liver-related mortality in non-alcoholic fatty liver disease. J Hepatol 2008;49:608-612.
10. Rafiq N, Bai C, Fang Y, Srishord M, McCullough A, Gramlich T, Younossi ZM. Long-term follow-up of patients with nonalcoholic fatty liver. Clin Gastroenterol Hepatol 2009;7:234-238.
11. Targher G, Bertolini L, Padovani R. Relation of nonalcoholic hepatic steatosis to early carotid atherosclerosis in healthy men. Role of visceral fat accumulation. Diabetes Care 2004;7: 1498-1500.
12. Brea A, Mosquera D, Martin E. Non alcoholic fatty liver disease is associated with carotid atherosclerosis. A casecontrol study. Arterioscler Thromb Vasc Biol 2005;25:1045-1050. (Pubitemid 40627853)
13. Yki-Jarvinen H, Westerbacka J. The fatty liver and insulin resistance. Curr Mol Med 2005;5:287-295. (Pubitemid 40667509)
14. Sattar N, Scherbakova O, Ford I. Elevated alanine aminotransferase predicts new-onset type 2 diabetes independently of classical risk factors, metabolic syndrome, and C-reactive protein in the West of Scotland Coronary Prevention Study. Diabetes 2004;53:2855-2860. (Pubitemid 39425910)
15. Narasimhan S, Gokulakrishnan K, Sampathkumar R, Farooq S, Ravikumar R, Mohan V, Balasubramanyam M. Oxidative stress is independently associated with non-alcoholic fatty liver disease (NAFLD) in subjects with and without type 2 diabetes. Clin Biochem 2010;43:815-821.
16. Yesilova Z, Yaman H, Oktenli C, Ozcan A, Uygun A, Cakir E, Sanisoglu SY, Erdil A, Ates Y, Aslan M, Musabak U, Erbil MK, Karaeren N, Dagalp K. Systemic markers of lipid peroxidation and antioxidants in patients with nonalcoholic fatty liver disease. Am J Gastroenterol 2005;100:850-855. (Pubitemid 40592378)
17. Eccleston HB, Andringa KK, Betancourt AM, King AL, Mantena SK, Swain TM, Tinsley HN, Nolte RN, Nagy TR, Abrams GA, Bailey SM. Chronic exposure to a high fat diet induces hepatic steatosis, impairs nitric oxide bioavailability, and modifies the mitochondrial proteome in mice. Antioxid Redox Signal 2010;Oct 4. [Epub ahead of print].
18. Zafarullaha M, Lia WQ, Sylvestera J, and Ahmadb M. Molecular mechanism of N-acetylcysteine actions. Cell Mol Life Sci 2003;60:6-20.
19. Musso G, Gambino R, Durazzo M. Adipokines in NASH: Post-prandial lipid metabolism as a link between adiponectin and liver disease. Hepatology 2005; 42:1175-1183. (Pubitemid 43112685)
20. Pagano C, Soardo G, Esposito W, Fallo F, Basan L, Donnini D, Federspil G, Sechi LA, Vettor R. Plasma adiponectin is decreased in nonalcoholic fatty liver disease. Eur J Endocrinol 2005;152:113-118. (Pubitemid 40185459)
21. Hoekstra R, Chamuleau RA. Recent developments on human cell lines for the bioartificial liver. Int J Artif Organs 2002;25:182-191. (Pubitemid 34456094)
22. Gomez-Lechon MJ, Donato M.T, Martinez-Romero A, Jimenez N, Castell JV, O'Connor JE. A human hepatocellular in vitro model to investigate steatosis. Chemico-biol Int 2007;165:106-116. (Pubitemid 46072796)
23. Donnini D, Perrella G, Stel G, Ambesi-Impiombato FS, Curcio F. A new model of human aortic endothelial cells in vitro. Biochimie 2000; 82:1107-1114. (Pubitemid 32015727)
24. Pastore A, Federici G, Bertini E, Piemonte F. Analysis of glutathione: Implication in redox and detoxification. Clin Chim Acta 2003; 333:19-39. (Pubitemid 36694824)
25. Piemonte F, Petrini S, Gaeta LM, Tozzi G, Bertini E, Devito R, Boldrini R, Marcellini M, Ciacco E, Nobili V. Protein glutathionylation increases in the liver of patients with nonalcoholic fatty liver disease. Hepatology 2008;23:457-464.
26. Kondo T, Hirose M, Kageyama K. Roles of oxidative stress and redox regulation in atherosclerosis. J Atheroscler Thromb 2009;16:532-538.
27. Targher G, Bertolini L, Rodella S, Zoppini G, Scala L, Zenari L, Falezza G. Association between plasma adiponectin concentrations and liver histology in patients with nonalcoholic fatty liver disease. Clin Endocrinol 2006;64:679-683. (Pubitemid 43775007)
28. Hwang SJ, Ballantyne CM, Sharrett AR, Smith LC, Davis CE, Gotto AM, Jr, Boerwinkle E. Circulating adhesion molecules VCAM-1, ICAM-1 and E-selectin in carotid atherosclerosis and incident coronary heart disease cases. Circulation 1997;96:4219-4225. (Pubitemid 28007447)
29. Sookoian S, Castaño GO, Burgueñ o AL, Rosselli MS, Gianotti TF, Mallardi P, Martino JS, Pirola CJ. Circulating levels and hepatic expression of molecular mediators of atherosclerosis in nonalcoholic fatty liver disease. Atherosclerosis 2010;209:585-591.
30. Alessi M.C, Bastelica D, Mavri A, Morange P, Berthet B, Grino M, Juhan-vague I. Plasma PAI-1 levels are more strongly related to liver steatosis than to adipose tissue accumulation. Arterioscler Thromb Vasc Biol 2003;23:1262-1268. (Pubitemid 36873814)
31. Thuy S, Ladurner R, Volynets V, Wagner S, Strahl S, Konigsrainer A, Maier K.P, Bischoff S.C, Berheim I. Nonalcoholic fatty liver disease in humans is associated with increased plasma endotoxin and plasminogen activator inhibitor 1 concentrations and with fructose intake. J Nutrition 2008;1452-1455.
32. Calamita G, Portincasa P. Present and future therapeutic strategies in non-alcoholic fatty liver disease. Expert Opin Ther Targets 2007;11:1231-1249. (Pubitemid 47527327)
33. Sanyal AJ, Chalasani N, Kowdley KV, McCullough A, Diehl A M, Bass NM, Neuschwander-Tetri BA, Lavine JE, Tonascia J, Unalp A, Van Natta M, Clark J, Brunt EM,. Kleiner DE,. Hoofnagle JH, and. Robuck P R. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N Engl J Med 2010;362:1675-1685.
34. Nan YM, Wu WJ, Fu N, Liang BL, Wang RQ, Li LX, Zhao SX, Zhao JM, Yu J. Antioxidants vitamin E and 1- aminobenzotriazole prevent experimental non-alcoholic steatohepatitis in mice. Scand J Gastroenterol 2009;44:1121-1131.